Automate Your Wheel Strategy on INCY
With Tiblio's Option Bot, you can configure your own wheel strategy including INCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INCY
- Rev/Share 23.6519
- Book/Share 30.0297
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.149
- MktCap 14624219640.0
- FreeCF/Share 1.4898
- PFCF 50.6361
- PE 16.6703
- Debt/Assets 0.0
- DivYield 0
- ROE 0.3386
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INCY | Barclays | -- | Overweight | -- | $90 | Aug. 1, 2025 |
| Upgrade | INCY | Stifel | Hold | Buy | -- | $107 | June 16, 2025 |
| Downgrade | INCY | Guggenheim | Buy | Neutral | -- | -- | March 18, 2025 |
| Downgrade | INCY | William Blair | Outperform | Market Perform | -- | -- | March 18, 2025 |
| Initiation | INCY | UBS | -- | Neutral | -- | $77 | Dec. 17, 2024 |
| Initiation | INCY | Wolfe Research | -- | Outperform | -- | $84 | Oct. 1, 2024 |
| Downgrade | INCY | Truist | Buy | Hold | $83 | $74 | Sept. 18, 2024 |
News
Why Incyte (INCY) is a Top Value Stock for the Long-Term
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor Relations Mohamed Issa - Executive Vice President & Head of U.S. Oncology Pablo J. Cagnoni - President and Head of Research & Development William Meury - CEO, President & Director Conference Call Participants Brian Corey Abrahams - RBC Capital Markets, Research Division Conor Thomas MacKay - BMO Capital Markets Equity Research David Neil Lebowitz - Citigroup Inc., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jay …
Read More
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Read More
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Read More
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
INCY or TECH: Which Is the Better Value Stock Right Now?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Incyte (INCY) or Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: July 02, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Read More
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
Read More
FDA Extends INCY's Application for Opzelura Label Expansion
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.
Read More
Incyte Says FDA Extended Review Period for Opzelura
Published: June 20, 2025 by: Market Watch
Sentiment: Negative
Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11.
Read More
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
Read More
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Published: June 18, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). "Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without.
Read More
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
Read More
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025.
Read More
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Read More
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Read More
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
Published: May 15, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.
Read More
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Read More
Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Incyte (INCY) Q1 Earnings and Revenues Top Estimates
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago.
Read More
Why Incyte Stock Was Tanking This Week
Published: March 21, 2025 by: The Motley Fool
Sentiment: Neutral
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open.
Read More
Incyte Is Today's Worst S&P 500 Stock. Here's Why.
Published: March 17, 2025 by: Barrons
Sentiment: Negative
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
Read More
Incyte Stock Eyes Worst Day Since 2018 After Trial Results
Published: March 17, 2025 by: Schaeffers Research
Sentiment: Negative
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.
Read More
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
Published: March 17, 2025 by: Benzinga
Sentiment: Positive
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
Read More
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
Read More
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
Read More
About Incyte Corporation (INCY)
- IPO Date 1993-11-04
- Website https://www.incyte.com
- Industry Biotechnology
- CEO Herve Hoppenot
- Employees 2617